THTX

Theratechnologies Inc. (THTX) | Rumor.io

Theratechnologies

THTX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about THTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 9

Theratechnologies Inc. reported Q2 2025 financial results, with sales of $17.73M beating estimates, but a net loss of $4.46M compared to a profit of $987K in the prior year.
The company's sales were driven by a SUGP contract, which was a significant contributor to the revenue.
The net loss was attributed to various factors, including increased operating expenses and a decrease in profit compared to the prior year.

Generated by AI

Sentiment

Of the messages about THTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.63% -6.25
Bearish	—	—	—	13.37% +6.25

Bullish· Jul 3

Theratechnologies Inc. (THTX) is entering a market with unmet medical need, giving its lead candidate for neutropenic enterocolitis a potential advantage if clinical trials are successful.
The company has agreed to a buyout deal with Future Pak, with shareholders set to receive $3.01 in cash plus a contingent value right worth up to $1.19 per share, a 216% premium over the closing price before the initial proposal.
THTX has the potential to reach $3.80-$4.20 USD depending on CVR and FX, making it a promising investment opportunity for those willing to hold onto the stock for a few months.

Bearish· Apr 14

$THTX has a history of generating liquidity to the upside, only to send it down later.
Investors who sold $THTX on a gap up this morning are now back to cash, indicating a lack of confidence in the stock's short-term prospects.
The stock's management has a history of prioritizing their own interests over those of shareholders, which could lead to a toxic takeover or other negative outcomes.

Generated by AI

Topics

Of the messages about THTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0.52%
Announcements	—	—	—	72.57%
Controversies	—	—	—	1.68%
Earnings	—	—	—	0.78%
Macro	—	—	—	0%
Technical Analysis	—	—	—	24.45%

Announcements· Jul 3

Theratechnologies Inc. ($THTX) has entered into a definitive agreement to be acquired by CB Biotechnology, an affiliate of Future Pak, for $3.01 per share in cash plus up to $1.19 per share in contingent value rights.
The total potential transaction value is $254 million, representing a 126% premium to the closing price on April 10, 2025, when CB Biotechnology first disclosed its interest in buying the company.
The acquisition is expected to close during Theratechnologies' Q4 ending November 30, 2025, and will be subject to shareholder approval and regulatory review.

Technical Analysis· Feb 4

$THTX is showing strong price action and decent volume in the premarket, with a premarket high of 4.84 and possible support around 3.50.
The stock's chart and volume are screaming for a bounce off of 2.70, with a potential lost cause if it doesn't happen.
$THTX is expected to test the 3.60-3.80 area again, with some traders considering it a strong buy or a starter position, while others see it as a garbage stock likely going lower.

Generated by AI

Community

Of the messages about THTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	15.07%
Newcomers	—	—	—	84.93%

Regulars· Dec 2

Theratechnologies Inc. has paused enrollment in its cancer drug trial due to efficacy and safety concerns, causing a 30% stock slump.
The company has filed a Form 6-K with the SEC, announcing an update from the ongoing TH1902 study, which has sparked a 3.6% stock pop.
Theratechnologies' stock has seen significant fluctuations, with a 19.9% drop and a 6.1% pop in the same day, with its Aroon indicator currently in a downtrend.

Newcomers· Feb 4

Newcomers are excited about Theratechnologies' lead peptide drug conjugate TH1902 receiving FDA Fast Track Designation for the treatment of sortilin-expressing cancers.
The designation is seen as a positive development for the company, with some users noting the potential for increased momentum and price appreciation.
Theratechnologies' stock price has been rising, with some users reporting gains of over 92% and others noting the stock's continued upward trend.

Generated by AI

Also Discussed

Investors talking about THTX also mention

#	Name	Attention
1	Milestone Pharmaceuticals Inc.MIST	0%+0
2	Shattuck Labs, Inc.STTK	0%new
3	Supernus Pharmaceuticals, Inc.SUPN	0%new
4	FMTO - Femto Technologies Inc.	——
5	BullFrog AI Holdings, Inc.BFRG	0%0
6	Bon Natural Life Ltd. Class A Ordinary SharesBON	0%0
7	CNTM - ConnectM Technology Solutions, Inc.	——
8	Odyssey Marine Exploration, Inc.OMEX	0%+0
9	Hoth Therapeutics Inc.HOTH	0%new
10	Global Engine Group Holding LimitedGLE	0%0